-Reuters
Vigil Neuroscience, Inc. Has Received A Response Letter From The FDA Regarding The Partial Clinical Hold On Its Drug VG-3927, Stating That Additional Non-Clinical Data Is Needed To Exceed The Maximum Exposure Limit In The Phase 1 Trial
- SEC FilingOn Thursday, October 12, 2023, Vigil Neuroscience, Inc. (the "Company") provided an update on the Company's small molecule TREM2 agonist, VG-3927. The Company announced that it received the 30-day